Odou P[au] - Search Results

Year	Number of Results
1996	2
1997	2
1998	1
1999	4
2000	1
2001	2
2002	2
2003	1
2004	2
2005	2
2006	3
2007	5
2008	4
2009	2
2010	4
2011	5
2012	8
2013	10
2014	10
2015	13
2016	11
2017	15
2018	15
2019	10
2020	18
2021	13

1

Rôle du pharmacien hospitalier dans le circuit d’une catégorie de Médicament de Thérapie Innovante : les lymphocytes T exprimant un Récepteur Chimérique à l’Antigène.

Pinturaud M, Vasseur M, Odou P. Pinturaud M, et al. Among authors: odou p. Bull Cancer. 2018 Dec;105 Suppl 2:S205-S213. doi: 10.1016/S0007-4551(19)30051-7. Bull Cancer. 2018. PMID: 30686359 French.

2

Occupational exposure to conventional antineoplastic drugs: can it be further limited?

Simon N, Odou P, Décaudin B, Bonnabry P, Fleury Souverain S. Simon N, et al. Among authors: odou p. Eur J Hosp Pharm. 2020 Sep;27(5):251-252. doi: 10.1136/ejhpharm-2019-002165. Epub 2019 Dec 16. Eur J Hosp Pharm. 2020. PMID: 32839255 No abstract available.

3

Traces pilot pharmacokinetic study dataset.

Gilliot S, Ducloy-Bouthors AS, Hennart B, Loingeville F, Jeanne M, Lebuffe G, Odou P. Gilliot S, et al. Among authors: odou p. Data Brief. 2020 Nov 1;33:106474. doi: 10.1016/j.dib.2020.106474. eCollection 2020 Dec. Data Brief. 2020. PMID: 33251299 Free PMC article.

4

[Reaction during dalbavancin infusion: About one case].

Valentin B, Dartus J, Trouillez T, Gaboriau L, Loiez C, Dezèque H, Odou P, Décaudin B, Migaud H, Genay S, Senneville E. Valentin B, et al. Among authors: odou p. Therapie. 2020 Jul 8:S0040-5957(20)30120-7. doi: 10.1016/j.therap.2020.06.015. Online ahead of print. Therapie. 2020. PMID: 32723578 French. No abstract available.

5

Instability of Insulin Aspart Diluted in Dextrose.

Préta LH, Henry H, Masse M, Barthélémy C, Carta N, Foulon C, Goossens JF, Kouach M, Lannoy D, Storme L, Décaudin B, Genay S, Odou P. Préta LH, et al. Among authors: odou p. Diabetes Care. 2020 Jul;43(7):e77-e78. doi: 10.2337/dc19-2462. Epub 2020 May 7. Diabetes Care. 2020. PMID: 32381586 No abstract available.

6

Long-term stability of ready-to-use 1-mg/mL midazolam solution.

Gilliot S, Masse M, Feutry F, Barthélémy C, Décaudin B, Genay S, Odou P. Gilliot S, et al. Among authors: odou p. Am J Health Syst Pharm. 2020 Apr 27;77(9):681-689. doi: 10.1093/ajhp/zxaa040. Am J Health Syst Pharm. 2020. PMID: 32300788

7

Efficiency of degradation or desorption methods in antineoplastic drug decontamination: A critical review.

Simon N, Odou P, Decaudin B, Bonnabry P, Fleury-Souverain S. Simon N, et al. Among authors: odou p. J Oncol Pharm Pract. 2019 Jun;25(4):929-946. doi: 10.1177/1078155219831427. Epub 2019 Feb 20. J Oncol Pharm Pract. 2019. PMID: 30786823 Review.

8

Chemical Decontamination of Hazardous Drugs: A Comparison of Solution Performances.

Simon N, Odou P, Decaudin B, Bonnabry P, Fleury-Souverain S. Simon N, et al. Among authors: odou p. Ann Work Expo Health. 2020 Feb 20;64(2):114-124. doi: 10.1093/annweh/wxz093. Ann Work Expo Health. 2020. PMID: 31848570

9

Evaluation of the stability of vancomycin solutions at concentrations used in clinical services.

Masse M, Genay S, Martin Mena A, Carta N, Lannoy D, Barthélémy C, Décaudin B, Odou P. Masse M, et al. Among authors: odou p. Eur J Hosp Pharm. 2020 Mar;27(e1):e87-e92. doi: 10.1136/ejhpharm-2019-002076. Epub 2020 Feb 5. Eur J Hosp Pharm. 2020. PMID: 32296513 Free PMC article. No abstract available.

10

Clinical implications of intravenous drug incompatibilities in critically ill patients.

Benlabed M, Perez M, Gaudy R, Genay S, Lannoy D, Barthélémy C, Odou P, Lebuffe G, Décaudin B. Benlabed M, et al. Among authors: odou p. Anaesth Crit Care Pain Med. 2019 Apr;38(2):173-180. doi: 10.1016/j.accpm.2018.04.003. Epub 2018 Apr 19. Anaesth Crit Care Pain Med. 2019. PMID: 29680262 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results